Overview

Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This trial uses a multi-center, randomized, double-blind, placebo, parallel-controlled design, and it is expected that about 105 cases will be enrolled in about 10 sites.
Phase:
Phase 2
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd